Search research articles
Contact Us
Filters
Showing results (301-310 of 354) with videos related to
Page
of 36
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 26, 2017
Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer
Suresh S Ramalingam, James C-H Yang, Chee Khoon Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 11, 2025
Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
Adithya Balasubramanian, Claire Marceaux, Sehrish Kanwal, et al.
International Journal of Molecular Sciences
|
February 10, 2024
The Gárdos Channel and Piezo1 Revisited: Comparison between Reticulocytes and Mature Red Blood Cells
Polina Petkova-Kirova, Nicoletta Murciano, Giulia Iacono, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 12, 2017
Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial
Federica Grosso, Nicola Steele, Silvia Novello, et al.
Nature Communications
|
February 27, 2023
Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial
Juliann Chmielecki, Tony Mok, Yi-Long Wu, et al.
BMJ Open
|
November 18, 2022
ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0/1 study characterising PD-L1 with <sup>89</sup>Zr-durvalumab (MEDI4736) PET/CT in stage III NSCLC patients receiving chemoradiation study protocol
Fiona Hegi-Johnson, Stacey E Rudd, Christian Wichmann, et al.
Plos One
|
August 13, 2013
The role of Cancer-Testis antigens as predictive and prognostic markers in non-small cell lung cancer
Thomas John, Maud H W Starmans, Yao-Tseng Chen, et al.
Journal of the National Cancer Institute
|
April 6, 2019
Combined Tumor Sequencing and Case-Control Analyses of RAD51C in Breast Cancer
Na Li, Simone McInerny, Magnus Zethoven, et al.
Cell Death Discovery
|
December 10, 2020
BCL-XL is an actionable target for treatment of malignant pleural mesothelioma
Surein Arulananda, Megan O'Brien, Marco Evangelista, et al.
Cell Death & Disease
|
April 26, 2019
BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival
Erinna F Lee, Tiffany J Harris, Sharon Tran, et al.
Page
of 36
Search research articles
Search
Showing results (301-310 of 354) with videos related to
Sort By:
Page
of 36
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 26, 2017
Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer
Suresh S Ramalingam, James C-H Yang, Chee Khoon Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 11, 2025
Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
Adithya Balasubramanian, Claire Marceaux, Sehrish Kanwal, et al.
International Journal of Molecular Sciences
|
February 10, 2024
The Gárdos Channel and Piezo1 Revisited: Comparison between Reticulocytes and Mature Red Blood Cells
Polina Petkova-Kirova, Nicoletta Murciano, Giulia Iacono, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 12, 2017
Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial
Federica Grosso, Nicola Steele, Silvia Novello, et al.
Nature Communications
|
February 27, 2023
Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial
Juliann Chmielecki, Tony Mok, Yi-Long Wu, et al.
BMJ Open
|
November 18, 2022
ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0/1 study characterising PD-L1 with <sup>89</sup>Zr-durvalumab (MEDI4736) PET/CT in stage III NSCLC patients receiving chemoradiation study protocol
Fiona Hegi-Johnson, Stacey E Rudd, Christian Wichmann, et al.
Plos One
|
August 13, 2013
The role of Cancer-Testis antigens as predictive and prognostic markers in non-small cell lung cancer
Thomas John, Maud H W Starmans, Yao-Tseng Chen, et al.
Journal of the National Cancer Institute
|
April 6, 2019
Combined Tumor Sequencing and Case-Control Analyses of RAD51C in Breast Cancer
Na Li, Simone McInerny, Magnus Zethoven, et al.
Cell Death Discovery
|
December 10, 2020
BCL-XL is an actionable target for treatment of malignant pleural mesothelioma
Surein Arulananda, Megan O'Brien, Marco Evangelista, et al.
Cell Death & Disease
|
April 26, 2019
BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival
Erinna F Lee, Tiffany J Harris, Sharon Tran, et al.
Page
of 36